var data={"title":"Plerixafor: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Plerixafor: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/372110?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=plerixafor-patient-drug-information\" class=\"drug drug_patient\">see &quot;Plerixafor: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6834097\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Mozobil</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20881778\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Mozobil</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6837685\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Hematopoietic Agent;</li>\n      <li>\n        Hematopoietic Stem Cell Mobilizer</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6837640\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing is based on actual body weight. Begin plerixafor after patient has received filgrastim for 4 days (refer to Filgrastim monograph for filgrastim dose); plerixafor, filgrastim, and apheresis should be continued daily until sufficient cell collection up to a maximum of 4 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hematopoietic stem cell mobilization (in non-Hodgkin lymphoma and multiple myeloma):</b> SubQ: Administer ~11 hours prior to apheresis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients &le;83 kg: 20 mg fixed dose <b>or</b> 0.24 mg/kg once daily for up to 4 consecutive days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients &gt;83 kg: 0.24 mg/kg once daily for up to 4 consecutive days; maximum dose: 40 mg daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6837641\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6837642\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Creatinine clearance estimate based on Cockcroft-Gault formula:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &le;50 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients &le;83 kg: 13 mg fixed dose <b>or</b> 0.16 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients &gt;83 kg and &lt;160 kg: 0.16 mg/kg once daily; maximum dose: 27 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20881798\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20881799\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">The manufacturer recommends calculating the dose based on actual weight for patients weighing up to 175% of ideal body weight (maximum dose: 40 mg daily). Dosing in patients &gt;175% of ideal body weight has not been studied.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6837648\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mozobil: 24 mg/1.2 mL (1.2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6837608\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6837643\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Administer subcutaneously, ~11 hours prior to initiation of apheresis. In some clinical trials, plerixafor administration began in the evening prior to apheresis; filgrastim was begun on day 1, plerixafor initiated in the evening on day 4 and apheresis in the morning on day 5; with filgrastim, plerixafor, and apheresis then continued daily until sufficient cell collection for autologous transplant (DiPersio 2009a; DiPersio 2009b).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132750\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving and a protective gown are required during administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6837609\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Peripheral stem cell mobilization:</b> Mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous transplantation (in combination with filgrastim) in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6837619\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reactions reported with filgrastim combination therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (27%), headache (22%), dizziness (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (37%), nausea (34%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (34%, including edema, erythema, hematoma, hemorrhage, induration, inflammation, irritation, pain, paresthesia, pruritus, skin rash, urticaria)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Insomnia (7%), malaise (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema (&lt;5%), hyperhidrosis (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (10%), flatulence (7%), abdominal distension (&lt;5%), abdominal distress (&lt;5%), abdominal pain (&lt;5%), constipation (&lt;5%), dyspepsia (&lt;5%), oral hypoesthesia (&lt;5%), xerostomia (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hyperleukocytosis (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Musculoskeletal pain (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal dreams, anaphylaxis, diaphoresis, dyspnea, hypersensitivity reaction, hypoxia, leukocytosis, nightmares, orthostatic hypotension, periorbital swelling, syncope, thrombocytopenia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6837615\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">History of hypersensitivity to plerixafor or any component of the formulation (anaphylactic shock has occurred).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6837616\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactic shock/hypersensitivity: Serious hypersensitivity reactions, including anaphylactic-type reactions (may be life-threatening with serious hypotension and shock) have been reported. Observe patients for hypersensitivity symptoms during, for 30 minutes after administration, and until clinically stable. Medication, personnel, and equipment for hypersensitivity management should be immediately available. Mild-to-moderate allergic reactions may also occur, usually within 30 minutes of administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Increases circulating leukocytes when used in conjunction with filgrastim; monitor WBC counts. Thrombocytopenia has been observed; monitor platelet counts.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Splenic enlargement/rupture: Cases of splenomegaly and/or splenic rupture have been reported with plerixafor when used in conjunction with filgrastim; instruct patients to report left upper quadrant pain or scapular/shoulder tip pain; promptly evaluate in any patient who report these symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Leukemia: Not intended for mobilization in patients with leukemia; may contaminate apheresis product by mobilizing leukemic cells.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Primary route of elimination is renal; dosage reduction is recommended in patients with moderate-to-severe renal impairment (CrCl &le;50 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxic drugs: Medications that may reduce renal function or compete for active tubular secretion may increase serum concentrations of plerixafor.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obese patients: Use has not been studied in patients weighing &gt;175% of ideal body weight.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor cell mobilization: When used in combination with filgrastim, tumor cells released from marrow could be collected in leukapheresis product; potential effect of tumor cell reinfusion is unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299889\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6840026\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9517&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6837610\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6837611\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have been observed in animal reproduction studies. May cause fetal harm if administered to pregnant women. Women of reproductive potential should use effective contraceptive measures to avoid becoming pregnant during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6837614\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if plerixafor is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, a decision should be made to discontinue plerixafor or to discontinue breastfeeding, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6837646\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelets; monitor for signs/symptoms of hypersensitivity (during, for 30 minutes after administration, and until clinically stable) and for signs/symptoms of splenomegaly</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6837636\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Plerixafor reversibly inhibits binding of stromal cell-derived factor-1-alpha (SDF-1&alpha;), expressed on bone marrow stromal cells, to the CXC chemokine receptor 4 (CXCR4), resulting in mobilization of hematopoietic stem and progenitor cells from bone marrow into peripheral blood. Plerixafor used in combination with filgrastim results in synergistic increase in CD34+ cell mobilization. Mobilized CD34+ cells are capable of engrafting with extended repopulating capacity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6837626\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Peak CD34+ mobilization (healthy volunteers): Plerixafor monotherapy: 6 to 9 hours after administration; Plerixafor + filgrastim: 10 to 14 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Sustained elevation in CD34+ cells (healthy volunteers): 4 to 18 hours after administration </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: SubQ: Rapid; exposure using the mg/kg dosing increases with increasing body weight; the fixed dosing (20 mg) results in higher exposure than the mg/kg dose, but the median time to reach the target cell count is the same for both dosing regimens </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: 0.3 L/kg; primarily to extravascular fluid space</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &le;58%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Not metabolized</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: 3 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: SubQ: 30 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~70%; as parent drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321891\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Mozobil Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">24 mg/1.2 mL (1.2 mL): $9,162.18</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961944\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Mozobil (AR, AT, AU, BB, BE, BR, CR, CY, CZ, DE, DK, DO, EE, ES, FR, GB, GT, HK, HN, HR, HU, IE, IL, IS, JP, KR, LB, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PL, PT, RO, SE, SG, SI, SK, SV, TH, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calandra G, McCarty J, McGuirk J, et al, &ldquo;AMD3100 Plus G-CSF Can Successfully Mobilize CD34+ Cells From Non-Hodgkin's Lymphoma, Hodgkin's Disease and Multiple Myeloma Patients Previously Failing Mobilization With Chemotherapy and/or Cytokine Treatment: Compassionate Use Data,&rdquo; <i>Bone Marrow Transplant</i>, 2008, 41(4):331-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/plerixafor-drug-information/abstract-text/17994119/pubmed\" target=\"_blank\" id=\"17994119\">17994119</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cashen A, Lopez S, Gao F, et al, &ldquo;A Phase II Study of Plerixafor (AMD3100) Plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization in Patients With Hodgkin Lymphoma,&rdquo; <i>Biol Blood Marrow Transplant</i>, 2008, 14(11):1253-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/plerixafor-drug-information/abstract-text/18940680/pubmed\" target=\"_blank\" id=\"18940680\">18940680</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Devine SM, Flomenberg N, Vesole DH, et al, &ldquo;Rapid Mobilization of CD34+ Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma,&rdquo; <i>J Clin Oncol</i>, 2004, 22(6):1095-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/plerixafor-drug-information/abstract-text/15020611/pubmed\" target=\"_blank\" id=\"15020611\">15020611</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Devine SM, Vij R, Rettig M, et al, &ldquo;Rapid Mobilization of Functional Donor Hematopoietic Cells Without G-CSF Using AMD3100, an Antagonist of the CXCR4/SDF-1 Interaction,&rdquo; <i>Blood</i>, 2008, 112(4):990-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/plerixafor-drug-information/abstract-text/18426988/pubmed\" target=\"_blank\" id=\"18426988\">18426988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DiPersio JF, Micallef I, Stiff PJ, et al, &ldquo;Phase III Prospective Randomized Double-Blinded Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin&rsquo;s Lymphoma,&rdquo; <i>J Clin Oncol</i>, 2009a, 27(28):4767-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/plerixafor-drug-information/abstract-text/19720922/pubmed\" target=\"_blank\" id=\"19720922\">19720922</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DiPersio JF, Stadtmauer EA, Nadamanee NP, et al, &ldquo;Plerixafor and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients With Multiple Myeloma,&rdquo; <i>Blood</i>, 2009b, 113(23):5720-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/plerixafor-drug-information/abstract-text/19363221/pubmed\" target=\"_blank\" id=\"19363221\">19363221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Douglas KW, Parker AN, Hayden PJ, et al, &ldquo;Plerixafor for PBSC Mobilisation in Myeloma Patients With Advanced Renal Failure: Safety and Efficacy Data in a Series of 21 Patients from Europe and the USA,&rdquo; <i>Bone Marrow Transplant,</i> 2012, 47(1):18-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/plerixafor-drug-information/abstract-text/21358693/pubmed\" target=\"_blank\" id=\"21358693\">21358693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flomenberg N, Devine SM, DiPersio JF, et al, &ldquo;The Use of AMD3100 Plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization is Superior to G-CSF Alone,&rdquo; <i>Blood</i>, 2005, 106(5):1867-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/plerixafor-drug-information/abstract-text/15890685/pubmed\" target=\"_blank\" id=\"15890685\">15890685</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    H&uuml;bel K, Fresen MM, Apperley JF, et al, &ldquo;European Data on Stem Cell Mobilization With Plerixafor in Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma and Multiple Myeloma Patients. A Subgroup Analysis of the European Consortium of Stem Cell Mobilization,&rdquo; <i>Bone Marrow Transplant</i>, 2012, 47(8):1046-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/plerixafor-drug-information/abstract-text/22080971/pubmed\" target=\"_blank\" id=\"22080971\">22080971</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lack NA, Green B, Dale DC, et al, &ldquo;A Pharmacokinetic-Pharmacodynamic Model for the Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100,&rdquo; <i>Clin Pharmacol Ther</i>, 2005, 77(5):427-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/plerixafor-drug-information/abstract-text/15900288/pubmed\" target=\"_blank\" id=\"15900288\">15900288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liles WC, Broxmeyer HE, Rodger E, et al, &ldquo;Mobilization of Hematopoietic Progenitor Cells in Healthy Volunteers by AMD3100, a CXCR4 Antagonist,&rdquo; <i>Blood</i>, 2003, 102(8):2728-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/plerixafor-drug-information/abstract-text/12855591/pubmed\" target=\"_blank\" id=\"12855591\">12855591</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mozobil (plerixafor) [prescribing information]. Cambridge, MA: Genzyme Corporation; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stiff PJ, Micallef I, Nademanee AP, et al, &ldquo;Transplanted CD34(+) Cell Dose is Associated With Long-Term Platelet Count Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma,&rdquo; <i>Biol Blood Marrow Transplant,</i> 2011, 17(8):1146-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/plerixafor-drug-information/abstract-text/21126595/pubmed\" target=\"_blank\" id=\"21126595\">21126595</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9517 Version 110.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6834097\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F20881778\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F6837685\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F6837640\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F6837641\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F6837642\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20881798\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20881799\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F6837648\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F6837608\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6837643\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132750\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F6837609\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6837619\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F6837615\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F6837616\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299889\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6840026\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F6837610\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6837611\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6837614\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6837646\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F6837636\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F6837626\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321891\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961944\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9517|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=plerixafor-patient-drug-information\" class=\"drug drug_patient\">Plerixafor: Patient drug information</a></li></ul></div></div>","javascript":null}